Demand for urinary retention therapeutics will increase through 2036, with anticholinergic and antispasmodic agents at 42.9% of the drug class in 2026. The market was valued at USD 4.02 billion in 2025 and is expected to be worth USD 9.00 billion by 2036, creating an incremental opportunity of USD 4.67 billion.